Tactical Therapeutics, Inc.
Clinical-stage oncology company developing an oral orotate-salt formulation of a small-molecule calcium-signaling inhibitor for malignant gliomas and other solid tumors. Development activities include preclinical xenograft efficacy and combination studies, Phase I/IB dose-escalation trials (single-agent and combined with chemotherapy and radiotherapy), serial pharmacokinetics and tumor-penetration measurements, imaging and transcriptional pharmacodynamic assessments, and integration of genomic and biomarker correlates to support further development and partnering.
Industries
Nr. of Employees
small (1-50)
Tactical Therapeutics, Inc.
Patents
Methods and compositions for treating SARS-CoV-2 infection using carboxyamidotriazole orotate
US-11318118-B1
View DetailsMethods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
US-10378059-B2
View DetailsCompositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
US-9089570-B2
View DetailsCompositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations
US-8912223-B2
View DetailsMethods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
US-8877785-B2
View Details
Methods and compositions for treating SARS-CoV-2 infection using carboxyamidotriazole orotate
US-11318118-B1
View DetailsMethods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
US-10378059-B2
View DetailsCompositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
US-9089570-B2
View DetailsCompositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations
US-8912223-B2
View DetailsMethods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
US-8877785-B2
View DetailsProducts
Oral orotate-salt formulation of a calcium-signaling small molecule
An orally administered small-molecule inhibitor of non–voltage-dependent calcium channels formulated as an orotate salt to increase aqueous solubility, oral bioavailability and reduce systemic toxicity compared with the parent hydrophobic compound; developed for central nervous system penetration.
Oral orotate-salt formulation of a calcium-signaling small molecule
An orally administered small-molecule inhibitor of non–voltage-dependent calcium channels formulated as an orotate salt to increase aqueous solubility, oral bioavailability and reduce systemic toxicity compared with the parent hydrophobic compound; developed for central nervous system penetration.
Services
Coordination and execution of Phase I/IB clinical trials, investigator collaborations and partner-focused program development for brain-penetrant oral small molecules.
Coordination and execution of Phase I/IB clinical trials, investigator collaborations and partner-focused program development for brain-penetrant oral small molecules.
Expertise Areas
- Early-phase oncology clinical trial management
- Pharmacokinetics and tissue-penetration studies for brain-penetrant agents
- Preclinical xenograft efficacy and combination therapy evaluation
- Biomarker-driven translational research and tumor genomic correlates
Key Technologies
- Cohort-based dose-escalation (3+3) clinical design
- Liquid chromatography–tandem mass spectrometry (LC–MS/MS)
- Plasma, tumor tissue and CSF concentration assays
- Subcutaneous and intracranial human tumor xenograft models
News & Updates
Late-breaking data on transcriptional pharmacodynamic markers and clinical observations presented in an AACR abstract/poster.
Presentation of development program to investor and philanthropic audiences focused on global health impact and partnership development.
Publication reporting safety, pharmacokinetics, intratumoral drug concentrations, recommended Phase II dose and preliminary efficacy signals from a Phase IB study combining an oral orotate-salt calcium-signaling inhibitor with temozolomide and chemoradiation in gliomas.
Preclinical and pharmacokinetic data comparing parent hydrophobic small molecule with its orotate-salt variant, showing increased AUC, higher Cmax and greater oral bioavailability for the orotate-salt formulation.
Preclinical reports describing enhanced antitumor activity and synergistic effects of orotate-salt formulations in combination with cytotoxic agents in glioblastoma and other xenograft models.
Intratumoral concentrations measured in surgical tumor specimens and CSF exceeded estimated therapeutic thresholds, supporting blood–brain barrier penetration.
Late-breaking data on transcriptional pharmacodynamic markers and clinical observations presented in an AACR abstract/poster.
Presentation of development program to investor and philanthropic audiences focused on global health impact and partnership development.
Publication reporting safety, pharmacokinetics, intratumoral drug concentrations, recommended Phase II dose and preliminary efficacy signals from a Phase IB study combining an oral orotate-salt calcium-signaling inhibitor with temozolomide and chemoradiation in gliomas.
Preclinical and pharmacokinetic data comparing parent hydrophobic small molecule with its orotate-salt variant, showing increased AUC, higher Cmax and greater oral bioavailability for the orotate-salt formulation.
Preclinical reports describing enhanced antitumor activity and synergistic effects of orotate-salt formulations in combination with cytotoxic agents in glioblastoma and other xenograft models.
Intratumoral concentrations measured in surgical tumor specimens and CSF exceeded estimated therapeutic thresholds, supporting blood–brain barrier penetration.